ANZEMET INJECTION Rx
Generic Name and Formulations:
Dolasetron mesylate 20mg/mL; IV inj.
Indications for ANZEMET INJECTION:
Prevention and treatment of post-op nausea & vomiting.
Give by IV inj, either undiluted 100mg over 30 seconds or diluted to 50mL and infused over up to 15 mins. ≥16yrs: Prevention: 12.5mg given as a single dose about 15 mins before stopping anesthesia. Treatment: 12.5mg as soon as needed.
May give by IV inj as in adult dose, or may be mixed into apple or apple-grape juice and taken orally (timing and doses are different; see full labeling). <2yrs: not established. 2–16yrs: Prevention: 0.35mg/kg IV (max 12.5mg) given as single dose about 15 mins before stopping anesthesia; or, 1.2mg/kg (max 100mg) mixed into apple or apple-grape juice and taken orally within 2hrs before surgery. Treatment: 0.35mg/kg IV as soon as needed.
Inj soln administered by IV: Prevention of nausea & vomiting associated with emetogenic cancer chemotherapy, including initial and repeat courses in adults and children.
Increased risk of developing QTc, PR and QRS interval prolongation. Avoid in patients with congenital QT syndrome, hypokalemia, hypomagnesemia, complete heart block or risk of (unless paced). Correct electrolyte imbalances prior to therapy. Monitor ECG periodically. CHF. Bradycardia. Pre-existing conduction abnormalities and underlying structural heart disease. Sick sinus syndrome. Atrial fibrillation with slow ventricular response. Recent MI. Renal impairment. Elderly. Pregnancy (Cat.B). Nursing mothers.
Caution with drugs which can prolong ECG intervals (eg, verapamil, flecainide, quinidine), diuretics, and with cumulative high-dose anthracycline therapy. Serotonin syndrome possible with concomitant serotonergic drugs (eg, SSRIs, SNRIs). Potentiated by cimetidine, atenolol (IV dolasetron). Antagonized by rifampin.
Selective 5-HT3 receptor antagonist.
Headache, dizziness, pain, fatigue, diarrhea, bradycardia, tachycardia, dyspepsia, chills/shivers, ECG changes, 2nd or 3rd-degree AV block; serotonin syndrome (discontinue if occurs).
Tabs—5; Single-use vials (100mg/5mL)—1; Single-use vials (12.5mg/0.625mL)—6; Multidose vial (500mg/25mL)—1
Sign Up for Free e-newsletters
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|